Published on 7 Nov 2021 on Forbes
Boom Or Kaboom? M&A Is Hitting Records – But Some Activists ‘Just Say No’
Although the leaders of both companies extolled the benefits of combining Merck’s clinical and...
Bristol Myers (BMY) sBLA for Reblozyl Gets Priority Review
Bristol Myers Squibb BMY recently announced that the FDA has accepted for priority review the sup...
10 Best Healthcare Stocks to Buy According to Greg Martinez’s Parkman Healthcare Partners
In this article, we discuss the 10 best healthcare stocks to buy according to Greg Martinez's Par...
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy...
Here's a roundup of top developments in the biotech space over the last 24 hours. Protagonist The...
Merck Completes Acquisition of Acceleron Pharma
Merck (MRK) revealed that it has completed the acquisition of Acceleron Pharma Inc. (XLRN) throug...
These 40 Mass. companies made the new Deloitte Fast 500 list - Boston Business Journal
Here are the 40 Bay State companies that made the latest installment of Deloitte's Technology Fas...
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial...
Here's a roundup of top developments in the biotech space over the last 24 hours: Merck & Co., In...
Here’s Why You Should Consider Investing in Acceleron Pharma (XLRN)
Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 ...
Boom Or Kaboom? M&A Is Hitting Records – But Some Activists ‘Just Say No’
Although the leaders of both companies extolled the benefits of combining Merck’s clinical and...
Boom Or Kaboom? M&A Is Hitting Records – But Some Activists ‘Just Say No’
Although the leaders of both companies extolled the benefits of combining Merck’s clinical and...
Why Earnings Season Could Be Great for Acceleron Pharma (XLRN)
Investors are always looking for stocks that are poised to beat at earnings season and Acceleron ...